Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer

Clinical Oncology

Volumn 26, Issue 9, 2014, Pages 551-559

  Sen, N ^a   Falk, S ^b   Abrams, R A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Adjuvant; Cancer; Chemoradiation; Neoadjuvant; Pancreatic

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOXANTRONE;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES; ADJUVANT THERAPY; CHEMORADIOTHERAPY; PANCREATIC NEOPLASMS; PROGNOSIS;

CHEMORADIOTHERAPY; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 84905592352     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.06.003     Document Type: Article

References (44)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2010 2013, National Cancer Institute.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
3. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378(9791):607-620.
4. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1200-1210.
5. Oettle H., Neuhaus P., Hochhaus A., et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013, 310(14):1473-1481.
6. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230(6):776-782.
7. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277.
8. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189(1):1-7.
9. Tepper J., Nardi G., Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976, 37(3):1519-1524.
10. Whittington R., Bryer M.P., Haller D.G., Solin L.J., Rosato E.F. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991, 21(5):1137-1143.
11. Griffin J.F., Smalley S.R., Jewell W., et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66(1):56-61.
12. Van den broeck A., Sergeant G., Ectors N., Van steenbergen W., Aerts R., Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009, 35(6):600-604.
13. Westerdahl J., Andrén-sandberg A., Ihse I. Recurrence of exocrine pancreatic cancer - local or hepatic?. Hepatogastroenterology 1993, 40(4):384-387.
14. Hishinuma S., Ogata Y., Tomikawa M., Ozawa I., Hirabayashi K., Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006, 10(4):511-518.
15. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120(8):899-903.
16. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4(6):567-579.
17. Conlon K.C., Klimstra D.S., Brennan M.F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996, 223(3):273-279.
18. Shahrudin M.D. Carcinoma of the pancreas: resection outcome at the University Hospital Kuala Lumpur. Int Surg 1997, 82(3):269-274.
19. Moghanaki D., Mick R., Furth E.E., et al. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. JOP 2011, 12(5):438-444.
20. Riediger H., Keck T., Wellner U., et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009, 13(7):1337-1344.
21. Berger A.C., Garcia M., Hoffman J.P., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008, 26(36):5918-5922.
22. Regine W.F., Winter K.A., Abrams R., et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011, 18(5):1319-1326.
23. Abrams R.A. Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma. Cancer J 2012, 18(6):624-632.
24. Morak M.J., Van der gaast A., Incrocci L., et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 2008, 248(6):1031-1041.
25. Morak M.J., Pek C.J., Kompanje E.J., Hop W.C., Kazemier G., Van eijck C.H. Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study. Cancer 2010, 116(4):830-836.
26. Neoptolemos J.P., Moore M.J., Cox T.F., et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012, 308(2):147-156.
27. Darby S., Mcgale P., Correa C., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378(9804):1707-1716.
28. Abrams R.A., Grochow L.B. Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg Clin North Am 1995, 75(5):925-938.
29. Smeenk H.G., Van eijck C.H., Hop W.C., et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007, 246(5):734-740.
30. Abrams R.A., Winter K.A., Regine W.F., et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704 - a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2012, 82(2):809-816.
31. Yovino S., Maidment B.W., Herman J.M., et al. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 2012, 83(3):916-920.
32. Abelson J.A., Murphy J.D., Minn A.Y., et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2012, 82(4):e595-601.
33. Poppe M.M., Narra V., Yue N.J., Zhou J., Nelson C., Jabbour S.K. A comparison of helical intensity-modulated radiotherapy, intensity-modulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer. Med Dosim 2011, 36(4):351-357.
34. Riall T.S., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma - part 3: update on 5-year survival. J Gastrointest Surg 2005, 9(9):1191-1204.
35. Corsini M.M., Miller R.C., Haddock M.G., et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008, 26(21):3511-3516.
36. Ishikawa O., Ohigashi H., Imaoka S., et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?. Arch Surg 1994, 129(10):1075-1080.
37. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3496-3502.
38. Brunner T.B., Golcher H., Witzigmann H., et al. Results of a multicenter randomized phase II trial of resection ± neoadjuvant chemoradiation therapy in pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, 84:S90-S91.
39. Hong T.S., Ryan D.P., Blaszkowsky L.S., et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys 2011, 79(1):151-157.
40. Chuong M.D., Springett G.M., Freilich J.M., et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013, 86(3):516-522.
41. Ben-josef E., Schipper M., Francis I.R., et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, 84(5):1166-1171.
42. Assifi M.M., Lu X., Eibl G., Reber H.A., Li G., Hines O.J. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011, 150(3):466-473.
43. Gillen S., Schuster T., Meyer zum büschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7(4):e1000267.
44. Festa V., Andriulli A., Valvano M.R., et al. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP 2013, 14(6):618-625.